{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:42:01Z","timestamp":1770907321045,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03041-7","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T22:20:47Z","timestamp":1738189247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Developing Soluplus\u00ae-Based Microparticle Amorphous Solid Dispersions with High Drug Loading for Enhanced Celecoxib Dissolution via Electrospraying"],"prefix":"10.1208","volume":"26","author":[{"given":"Fan","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudong","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7987-8856","authenticated-orcid":false,"given":"Jiantao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"3041_CR1","doi-asserted-by":"publisher","unstructured":"Beig A, Fine-Shamir N, Lindley D, Miller JM, Dahan A. Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability. AAPS J. 2017;19:806\u201313. https:\/\/doi.org\/10.1208\/s12248-017-0052-1.","DOI":"10.1208\/s12248-017-0052-1."},{"key":"3041_CR2","doi-asserted-by":"publisher","unstructured":"Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5:442\u201353.\u00a0https:\/\/doi.org\/10.1016\/j.apsb.2015.07.003","DOI":"10.1016\/j.apsb.2015.07.003"},{"key":"3041_CR3","doi-asserted-by":"publisher","unstructured":"Stegemann S, Leveiller F, Franchi D, de Jong H, Lind\u00e9n H. When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci. 2007;31:249\u201361.\u00a0https:\/\/doi.org\/10.1016\/j.ejps.2007.05.110","DOI":"10.1016\/j.ejps.2007.05.110"},{"key":"3041_CR4","doi-asserted-by":"publisher","unstructured":"Pouton CW. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29:278\u201387.\u00a0https:\/\/doi.org\/10.1016\/j.ejps.2006.04.016","DOI":"10.1016\/j.ejps.2006.04.016"},{"key":"3041_CR5","doi-asserted-by":"publisher","unstructured":"Anane-Adjei AB, Jacobs E, Nash SC, Askin S, Soundararajan R, Kyobula M, et al. Amorphous solid dispersions: Utilization and challenges in preclinical drug development within AstraZeneca. Int J Pharm. 2022;614:121387.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121387","DOI":"10.1016\/j.ijpharm.2021.121387"},{"key":"3041_CR6","doi-asserted-by":"publisher","unstructured":"Bhujbal S V., Mitra B, Jain U, Gong Y, Agrawal A, Karki S, et al. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies. Acta Pharm Sin B. 2021;11:2505\u201336.\u00a0https:\/\/doi.org\/10.1016\/j.apsb.2021.05.014","DOI":"10.1016\/j.apsb.2021.05.014"},{"key":"3041_CR7","doi-asserted-by":"publisher","unstructured":"Tsume Y, Mudie DM, Langguth P, Amidon GE, Amidon GL. The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci. 2014;57:152\u201363.\u00a0https:\/\/doi.org\/10.1016\/j.ejps.2014.01.009","DOI":"10.1016\/j.ejps.2014.01.009"},{"key":"3041_CR8","doi-asserted-by":"publisher","unstructured":"Yang R, Mann AKP, Van Duong T, Ormes JD, Okoh GA, Hermans A, et al. Drug Release and Nanodroplet Formation from Amorphous Solid Dispersions: Insight into the Roles of Drug Physicochemical Properties and Polymer Selection. Mol Pharm. 2021;18:2066\u201381. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00055.","DOI":"10.1021\/acs.molpharmaceut.1c00055."},{"key":"3041_CR9","doi-asserted-by":"publisher","unstructured":"Schittny A, Huwyler J, Puchkov M. Mechanisms of increased bioavailability through amorphous solid dispersions: a review. Drug Deliv. 2020;27:110\u201327. https:\/\/doi.org\/10.1080\/10717544.2019.1704940.","DOI":"10.1080\/10717544.2019.1704940."},{"key":"3041_CR10","doi-asserted-by":"publisher","unstructured":"Alzahrani A, Nyavanandi D, Mandati P, Youssef AAA, Narala S, Bandari S, et al. A systematic and robust assessment of hot-melt extrusion-based amorphous solid dispersions: Theoretical prediction to practical implementation. Int J Pharm. 2022;624:121951.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121951","DOI":"10.1016\/j.ijpharm.2022.121951"},{"key":"3041_CR11","doi-asserted-by":"publisher","unstructured":"Kong Y, Wang W, Wang C, Li L, Peng D, Tian B. Supersaturation and phase behavior during dissolution of amorphous solid dispersions. Int J Pharm. 2023;631:122524.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122524","DOI":"10.1016\/j.ijpharm.2022.122524"},{"key":"3041_CR12","doi-asserted-by":"publisher","unstructured":"Deac A, Qi Q, Indulkar AS, Gao Y, Zhang GGZ, Taylor LS. Dissolution Mechanisms of Amorphous Solid Dispersions: A Close Look at the Dissolution Interface. Mol Pharm. 2023;20:2217\u201334. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00020.","DOI":"10.1021\/acs.molpharmaceut.3c00020."},{"key":"3041_CR13","doi-asserted-by":"publisher","unstructured":"Page S, Maurer R. Amorphous solid dispersions. Shah N, Sandhu H, Choi DS, Chokshi H, Malick AW, editors. New York, NY: Springer New York; 2014. https:\/\/doi.org\/10.1007\/978-1-4939-1598-9.","DOI":"10.1007\/978-1-4939-1598-9."},{"key":"3041_CR14","doi-asserted-by":"publisher","unstructured":"Mendonsa N, Almutairy B, Kallakunta VR, Sarabu S, Thipsay P, Bandari S, et al. Manufacturing strategies to develop amorphous solid dispersions: An overview. J Drug Deliv Sci Technol. 2020;55:101459.\u00a0https:\/\/doi.org\/10.1016\/j.jddst.2019.101459","DOI":"10.1016\/j.jddst.2019.101459"},{"key":"3041_CR15","doi-asserted-by":"publisher","unstructured":"Saboo S, Mugheirbi NA, Zemlyanov DY, Kestur US, Taylor LS. Congruent release of drug and polymer: A \u201csweet spot\u201d in the dissolution of amorphous solid dispersions. J Control Release. 2019;298:68\u201382.\u00a0https:\/\/doi.org\/10.1016\/j.jconrel.2019.01.039","DOI":"10.1016\/j.jconrel.2019.01.039"},{"key":"3041_CR16","doi-asserted-by":"publisher","unstructured":"Li S, Pollock-Dove C, Dong LC, Chen J, Creasey AA, Dai WG. Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: A case study. Mol Pharm. 2012;9:1100\u20138. https:\/\/doi.org\/10.1021\/mp200352q.","DOI":"10.1021\/mp200352q."},{"key":"3041_CR17","doi-asserted-by":"publisher","unstructured":"Petru\u0161evska M, Homar M, Petek B, Resman A, Kocjan D, Urleb U, et al. Hydroxypropyl methylcellulose mediated precipitation inhibition of sirolimus: From a screening campaign to a proof-of-concept human study. Mol Pharm. 2013;10:2299\u2013310. https:\/\/doi.org\/10.1021\/mp300641h.","DOI":"10.1021\/mp300641h."},{"key":"3041_CR18","doi-asserted-by":"publisher","unstructured":"Gan Y, Zhang X, Xu D, Zhang H, Baak JP, Luo L, et al. Evaluating supersaturation in vitro and predicting its performance in vivo with Biphasic gastrointestinal Simulator: A case study of a BCS IIB drug. Int J Pharm. 2020;578:119043.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119043","DOI":"10.1016\/j.ijpharm.2020.119043"},{"key":"3041_CR19","doi-asserted-by":"publisher","unstructured":"Dedroog S, Huygens C, Van den Mooter G. Chemically identical but physically different: A comparison of spray drying, hot melt extrusion and cryo-milling for the formulation of high drug loaded amorphous solid dispersions of naproxen. Eur J Pharm Biopharm. 2019;135:1\u201312.\u00a0https:\/\/doi.org\/10.1016\/j.ejpb.2018.12.002","DOI":"10.1016\/j.ejpb.2018.12.002"},{"key":"3041_CR20","doi-asserted-by":"publisher","unstructured":"Becelaere J, Van Den Broeck E, Schoolaert E, Vanhoorne V, Van Guyse JFR, Vergaelen M, et al. Stable amorphous solid dispersion of flubendazole with high loading via electrospinning. J Control Release. 2022;351:123\u201336.\u00a0https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.028","DOI":"10.1016\/j.jconrel.2022.09.028"},{"key":"3041_CR21","doi-asserted-by":"publisher","unstructured":"Becelaere J, Frateur O, Schoolaert E, Vanhoorne V, D\u2019hooge DR, Vervaet C, et al. Solvent electrospinning amorphous solid dispersions with high itraconazole, celecoxib, mebendazole and fenofibrate drug loading and release potential. J Control Release. 2023;362:268\u201377.\u00a0https:\/\/doi.org\/10.1016\/j.jconrel.2023.08.054","DOI":"10.1016\/j.jconrel.2023.08.054"},{"key":"3041_CR22","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.addr.2009.07.013","volume":"61","author":"S Chakraborty","year":"2009","unstructured":"Chakraborty S, Liao IC, Adler A, Leong KW. Electrohydrodynamics: a facile technique to fabricate drug delivery systems. Adv Drug Deliv Rev. 2009;61:1043\u201354. https:\/\/doi.org\/10.1016\/j.addr.2009.07.013.","journal-title":"Adv Drug Deliv Rev"},{"key":"3041_CR23","doi-asserted-by":"publisher","unstructured":"Rostamabadi H, Falsafi SR, Rostamabadi MM, Assadpour E, Jafari SM. Electrospraying as a novel process for the synthesis of particles\/nanoparticles loaded with poorly water-soluble bioactive molecules. Adv Colloid Interface Sci. 2021;290:102384.\u00a0https:\/\/doi.org\/10.1016\/j.cis.2021.102384","DOI":"10.1016\/j.cis.2021.102384"},{"key":"3041_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.04.026","volume":"176","author":"A Ali","year":"2021","unstructured":"Ali A, Zaman A, Sayed E, Evans D, Morgan S, Samwell C, et al. Electrohydrodynamic atomisation driven design and engineering of opportunistic particulate systems for applications in drug delivery, therapeutics and pharmaceutics. Adv Drug Deliv Rev. 2021;176: 113788. https:\/\/doi.org\/10.1016\/j.addr.2021.04.026.","journal-title":"Adv Drug Deliv Rev"},{"key":"3041_CR25","doi-asserted-by":"publisher","unstructured":"Almer\u00eda B, Gomez A. Electrospray synthesis of monodisperse polymer particles in a broad (60nm-2\u03bcm) diameter range: Guiding principles and formulation recipes. J Colloid Interface Sci. 2014;417:121\u201330.\u00a0https:\/\/doi.org\/10.1016\/j.jcis.2013.11.037","DOI":"10.1016\/j.jcis.2013.11.037"},{"key":"3041_CR26","doi-asserted-by":"publisher","unstructured":"Xue Y, Liao Y, Wang H, Li S, Gu Z, Adu\u2010Frimpong M, et al. Preparation and evaluation of astaxanthin\u2010loaded 2\u2010hydroxypropyl\u2010beta\u2010cyclodextrin and Soluplus\u00ae nanoparticles based on electrospray technology. J Sci Food Agric. 2023;103:3628\u201337. https:\/\/doi.org\/10.1002\/jsfa.12527.","DOI":"10.1002\/jsfa.12527."},{"key":"3041_CR27","doi-asserted-by":"publisher","unstructured":"Andrews GP, Qian K, Jacobs E, Jones DS, Tian Y. High drug loading nanosized amorphous solid dispersion (NASD) with enhanced in vitro solubility and permeability: Benchmarking conventional ASD. Int J Pharm. 2023;632:122551.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122551","DOI":"10.1016\/j.ijpharm.2022.122551"},{"key":"3041_CR28","doi-asserted-by":"publisher","unstructured":"Homayouni A, Sadeghi F, Varshosaz J, Afrasiabi Garekani H, Nokhodchi A. Promising dissolution enhancement effect of soluplus on crystallized celecoxib obtained through antisolvent precipitation and high pressure homogenization techniques. Colloids Surfaces B Biointerfaces. 2014;122:591\u2013600.\u00a0https:\/\/doi.org\/10.1016\/j.colsurfb.2014.07.037","DOI":"10.1016\/j.colsurfb.2014.07.037"},{"key":"3041_CR29","doi-asserted-by":"publisher","unstructured":"Kaljevi\u0107 O, Djuris J, \u010calija B, Lavri\u010d Z, Kristl J, Ibri\u0107 S. Application of miscibility analysis and determination of Soluplus solubility map for development of carvedilol-loaded nanofibers. Int J Pharm. 2017;533:445\u201354.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2017.05.017","DOI":"10.1016\/j.ijpharm.2017.05.017"},{"key":"3041_CR30","doi-asserted-by":"publisher","unstructured":"Gomaa E, Attia MS, Ghazy FES, Hassan AEA, Hasan AA. Pump-free electrospraying: A novel approach for fabricating Soluplus\u00ae-based solid dispersion nanoparticles. J Drug Deliv Sci Technol. 2022;67:103027.\u00a0https:\/\/doi.org\/10.1016\/j.jddst.2021.103027","DOI":"10.1016\/j.jddst.2021.103027"},{"key":"3041_CR31","doi-asserted-by":"publisher","unstructured":"Costa BLA, Sauceau M, Del Confetto S, Sescousse R, R\u00e9 MI. Determination of drug-polymer solubility from supersaturated spray-dried amorphous solid dispersions: A case study with Efavirenz and Soluplus\u00ae. Eur J Pharm Biopharm. 2019;142:300\u20136.\u00a0https:\/\/doi.org\/10.1016\/j.ejpb.2019.06.028","DOI":"10.1016\/j.ejpb.2019.06.028"},{"key":"3041_CR32","doi-asserted-by":"publisher","unstructured":"Zi P, Zhang C, Ju C, Su Z, Bao Y, Gao J, et al. Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant - Soluplus. Eur J Pharm Sci. 2019;134:233\u201345.\u00a0https:\/\/doi.org\/10.1016\/j.ejps.2019.04.022","DOI":"10.1016\/j.ejps.2019.04.022"},{"key":"3041_CR33","doi-asserted-by":"publisher","unstructured":"Lee JJ, Nam S, Park JH, Lee SY, Jeong JY, Lee JY, et al. Nanocomposites based on Soluplus and Angelica gigas Nakai extract fabricated by an electrohydrodynamic method for oral administration. J Colloid Interface Sci. 2016;484:146\u201354.\u00a0https:\/\/doi.org\/10.1016\/j.jcis.2016.08.080","DOI":"10.1016\/j.jcis.2016.08.080"},{"key":"3041_CR34","doi-asserted-by":"publisher","unstructured":"Nagy ZK, Balogh A, Vajna B, Farkas A, Patyi G, Kramarics \u00c1, et al. Comparison of electrospun and extruded soluplus\u00ae-based solid dosage forms of improved dissolution. J Pharm Sci. 2012;101:322\u201332.\u00a0https:\/\/doi.org\/10.1002\/jps.22731","DOI":"10.1002\/jps.22731"},{"key":"3041_CR35","doi-asserted-by":"publisher","unstructured":"Pisani S, Friuli V, Conti B, Bruni G, Maggi L. Tableted hydrophilic electrospun nanofibers to promote meloxicam dissolution rate. J Drug Deliv Sci Technol. 2021;66:102878.\u00a0https:\/\/doi.org\/10.1016\/j.jddst.2021.102878","DOI":"10.1016\/j.jddst.2021.102878"},{"key":"3041_CR36","doi-asserted-by":"publisher","unstructured":"Bruni G, Maggi L, Tammaro L, Lorenzo R Di, Friuli V, D\u2019Aniello S, et al. Electrospun fibers as potential carrier systems for enhanced drug release of perphenazine. Int J Pharm. 2016;511:190\u20137.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2016.07.011","DOI":"10.1016\/j.ijpharm.2016.07.011"},{"key":"3041_CR37","doi-asserted-by":"publisher","unstructured":"Tran P, Nguyen TN, Park J-S. Co-carrier-based solid dispersion of celecoxib improves dissolution rate and oral bioavailability in rats. J Drug Deliv Sci Technol. 2023;79:104073.\u00a0https:\/\/doi.org\/10.1016\/j.jddst.2022.104073","DOI":"10.1016\/j.jddst.2022.104073"},{"key":"3041_CR38","doi-asserted-by":"publisher","unstructured":"Brune K, Hinz B. Selective cyclooxygenase\u20102 inhibitors: similarities and differences. Scand J Rheumatol. 2004;33:1\u20136. https:\/\/doi.org\/10.1080\/03009740310004766.","DOI":"10.1080\/03009740310004766."},{"key":"3041_CR39","doi-asserted-by":"publisher","unstructured":"Homayouni A, Sadeghi F, Varshosaz J, Garekani HA, Nokhodchi A. Comparing various techniques to produce micro\/nanoparticles for enhancing the dissolution of celecoxib containing PVP. Eur J Pharm Biopharm. 2014;88:261\u201374.\u00a0https:\/\/doi.org\/10.1016\/j.jddst.2022.104073","DOI":"10.1016\/j.jddst.2022.104073"},{"key":"3041_CR40","doi-asserted-by":"publisher","unstructured":"Ghanavati R, Taheri A, Homayouni A. Anomalous dissolution behavior of celecoxib in PVP\/Isomalt solid dispersions prepared using spray drier. Mater Sci Eng C. 2017;72:501\u201311.\u00a0https:\/\/doi.org\/10.1016\/j.msec.2016.11.042","DOI":"10.1016\/j.msec.2016.11.042"},{"key":"3041_CR41","doi-asserted-by":"publisher","unstructured":"Raval N, Maheshwari R, Kalyane D, Youngren-Ortiz SR, Chougule MB, Tekade RK. Importance of Physicochemical Characterization of Nanoparticles in Pharmaceutical Product Development. Basic Fundam Drug Deliv. Elsevier; 2019. p. 369\u2013400.\u00a0https:\/\/doi.org\/10.1016\/B978-0-12-817909-3.00010-8","DOI":"10.1016\/B978-0-12-817909-3.00010-8"},{"key":"3041_CR42","doi-asserted-by":"publisher","unstructured":"Holm TP, Knopp MM, Berthelsen R, L\u00f6bmann K. Supersaturated amorphous solid dispersions of celecoxib prepared in situ by microwave irradiation. Int J Pharm. 2022;626:122115.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122115","DOI":"10.1016\/j.ijpharm.2022.122115"},{"key":"3041_CR43","doi-asserted-by":"publisher","unstructured":"Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123\u201333.\u00a0https:\/\/doi.org\/10.1016\/S0928-0987(01)00095-1","DOI":"10.1016\/S0928-0987(01)00095-1"},{"key":"3041_CR44","doi-asserted-by":"publisher","unstructured":"Sun DD, Wen H, Taylor LS. Non-Sink Dissolution Conditions for Predicting Product Quality and In Vivo Performance of Supersaturating Drug Delivery Systems. J Pharm Sci. 2016;105:2477\u201388. https:\/\/doi.org\/10.1016\/j.xphs.2016.03.024","DOI":"10.1016\/j.xphs.2016.03.024"},{"key":"3041_CR45","doi-asserted-by":"publisher","unstructured":"Liu J, Cao F, Zhang C, Ping Q. Use of polymer combinations in the preparation of solid dispersions of a thermally unstable drug by hot-melt extrusion. Acta Pharm Sin B. 2013;3:263\u201372.\u00a0https:\/\/doi.org\/10.1016\/j.apsb.2013.06.007","DOI":"10.1016\/j.apsb.2013.06.007"},{"key":"3041_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jconrel.2010.03.014","volume":"145","author":"YH Lee","year":"2010","unstructured":"Lee YH, Mei F, Bai MY, Zhao S, Chen DR. Release profile characteristics of biodegradable-polymer-coated drug particles fabricated by dual-capillary electrospray. J Control Release. 2010;145:58\u201365. https:\/\/doi.org\/10.1016\/j.jconrel.2010.03.014.","journal-title":"J Control Release"},{"key":"3041_CR47","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.progpolymsci.2012.03.002","volume":"37","author":"N Bock","year":"2012","unstructured":"Bock N, Dargaville TR, Woodruff MA. Electrospraying of polymers with therapeutic molecules: State of the art. Prog Polym Sci. 2012;37:1510\u201351. https:\/\/doi.org\/10.1016\/j.progpolymsci.2012.03.002.","journal-title":"Prog Polym Sci"},{"key":"3041_CR48","doi-asserted-by":"publisher","unstructured":"Kaushal AM, Chakraborti AK, Bansal AK. FTIR studies on differential intermolecular association in crystalline and amorphous states of structurally related non-steroidal anti-inflammatory drugs. Mol Pharm. 2008;5:937\u201345. https:\/\/doi.org\/10.1021\/mp800098d.","DOI":"10.1021\/mp800098d."},{"key":"3041_CR49","doi-asserted-by":"publisher","unstructured":"Andrews GP, Abu-Diak O, Kusmanto F, Hornsby P, Hui Z, Jones DS. Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions. J Pharm Pharmacol. 2010;62:1580\u201390.\u00a0https:\/\/doi.org\/10.1111\/j.2042-7158.2010.01177.x","DOI":"10.1111\/j.2042-7158.2010.01177.x"},{"key":"3041_CR50","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejpb.2017.06.010","volume":"119","author":"A Smeets","year":"2017","unstructured":"Smeets A, Clasen C, Van den Mooter G. Electrospraying of polymer solutions: Study of formulation and process parameters. Eur J Pharm Biopharm. 2017;119:114\u201324. https:\/\/doi.org\/10.1016\/j.ejpb.2017.06.010.","journal-title":"Eur J Pharm Biopharm"},{"key":"3041_CR51","doi-asserted-by":"publisher","unstructured":"Bock N, Woodruff MA, Hutmacher DW, Dargaville TR. Electrospraying, a Reproducible Method for Production of Polymeric Microspheres for Biomedical Applications. Polymers (Basel). 2011;3:131\u201349.\u00a0https:\/\/doi.org\/10.3390\/polym3010131","DOI":"10.3390\/polym3010131"},{"key":"3041_CR52","doi-asserted-by":"publisher","unstructured":"Yu DG, Yang JM, Branford-White C, Lu P, Zhang L, Zhu LM. Third generation solid dispersions of ferulic acid in electrospun composite nanofibers. Int J Pharm. 2010;400:158\u201364.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2010.08.010","DOI":"10.1016\/j.ijpharm.2010.08.010"},{"key":"3041_CR53","doi-asserted-by":"publisher","unstructured":"Yu D-G, Li J-J, Williams GR, Zhao M. Electrospun amorphous solid dispersions of poorly water-soluble drugs: A review. J Control Release. 2018;292:91\u2013110.\u00a0https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.016","DOI":"10.1016\/j.jconrel.2018.08.016"},{"key":"3041_CR54","doi-asserted-by":"publisher","unstructured":"D\u00e9muth B, Farkas A, Pataki H, Balogh A, Szab\u00f3 B, Borb\u00e1s E, et al. Detailed stability investigation of amorphous solid dispersions prepared by single-needle and high speed electrospinning. Int J Pharm. 2016;498:234\u201344.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2015.12.029","DOI":"10.1016\/j.ijpharm.2015.12.029"},{"key":"3041_CR55","doi-asserted-by":"publisher","unstructured":"Janssens S, De Zeure A, Paudel A, Van Humbeeck J, Rombaut P, Van Den Mooter G. Influence of preparation methods on solid state supersaturation of amorphous solid dispersions: A case study with itraconazole and eudragit E100. Pharm Res. 2010;27:775\u201385. https:\/\/doi.org\/10.1007\/s11095-010-0069-y.","DOI":"10.1007\/s11095-010-0069-y."},{"key":"3041_CR56","doi-asserted-by":"publisher","unstructured":"Xu J, Li K, Liu M, Gu X, Li P, Fan Y. Studies on preparation and formation mechanism of poly(lactide-co-glycolide) microrods via one-step electrospray and an application for drug delivery system. Eur Polym J. 2021;148:110372.\u00a0https:\/\/doi.org\/10.1007\/s11095-010-0069-y","DOI":"10.1007\/s11095-010-0069-y"},{"key":"3041_CR57","doi-asserted-by":"publisher","unstructured":"Baird JA, Taylor LS. Evaluation of amorphous solid dispersion properties using thermal analysis techniques. Adv Drug Deliv Rev. 2012;64:396\u2013421.\u00a0https:\/\/doi.org\/10.1016\/j.addr.2011.07.009","DOI":"10.1016\/j.addr.2011.07.009"},{"key":"3041_CR58","doi-asserted-by":"publisher","unstructured":"Qian F, Huang J, Zhu Q, Haddadin R, Gawel J, Garmise R, et al. Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion? Int J Pharm. 2010;395:232\u20135.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2010.05.033","DOI":"10.1016\/j.ijpharm.2010.05.033"},{"key":"3041_CR59","doi-asserted-by":"publisher","unstructured":"Rask MB, Knopp MM, Olesen NE, Holm R, Rades T. Influence of PVP\/VA copolymer composition on drug-polymer solubility. Eur J Pharm Sci. 2016;85:10\u20137.\u00a0https:\/\/doi.org\/10.1016\/j.ejps.2016.01.026","DOI":"10.1016\/j.ejps.2016.01.026"},{"key":"3041_CR60","doi-asserted-by":"publisher","unstructured":"Steiner T. The Hydrogen Bond in the Solid State. Angew Chemie Int Ed. 2002;41:48\u201376. https:\/\/doi.org\/10.1002\/1521-3773(20020104)41:1%3C48::AID-ANIE48%3E3.0.CO;2-U.","DOI":"10.1002\/1521-3773(20020104)41:1%3C48::AID-ANIE48%3E3.0.CO;2-U."},{"key":"3041_CR61","doi-asserted-by":"publisher","unstructured":"Bristol AN, Lamm MS, Li Y. Impact of Hydroxypropyl Methylcellulose Acetate Succinate Critical Aggregation Concentration on Celecoxib Supersaturation. Mol Pharm. 2021;18:4299\u2013309. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00372.","DOI":"10.1021\/acs.molpharmaceut.1c00372."},{"key":"3041_CR62","doi-asserted-by":"publisher","unstructured":"He Y, Ho C. Amorphous Solid Dispersions: Utilization and Challenges in Drug Discovery and Development. J Pharm Sci. 2015;104:3237\u201358.\u00a0https:\/\/doi.org\/10.1002\/jps.24541","DOI":"10.1002\/jps.24541"},{"key":"3041_CR63","doi-asserted-by":"publisher","unstructured":"Nagy ZK, Balogh A, D\u00e9muth B, Pataki H, Vigh T, Szab\u00f3 B, et al. High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole. Int J Pharm. 2015;480:137\u201342.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2015.01.025","DOI":"10.1016\/j.ijpharm.2015.01.025"},{"key":"3041_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123941","volume":"655","author":"H Patel","year":"2024","unstructured":"Patel H, Raje V, Maczko P, Patel K. Application of 3D printing technology for the development of dose adjustable geriatric and pediatric formulation of celecoxib. Int J Pharm. 2024;655: 123941. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.123941.","journal-title":"Int J Pharm"},{"key":"3041_CR65","doi-asserted-by":"publisher","unstructured":"Ueda K, Moseson DE, Taylor LS. Amorphous solubility advantage: Theoretical considerations, experimental methods, and contemporary relevance. J Pharm Sci. 2025;114:18\u201339. https:\/\/doi.org\/10.1016\/j.xphs.2024.08.029","DOI":"10.1016\/j.xphs.2024.08.029"},{"key":"3041_CR66","doi-asserted-by":"publisher","unstructured":"Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm. 2007;66:334\u201347.\u00a0https:\/\/doi.org\/10.1016\/j.ejpb.2006.11.020","DOI":"10.1016\/j.ejpb.2006.11.020"},{"key":"3041_CR67","doi-asserted-by":"publisher","unstructured":"Zhu L, Jona J, Nagapudi K, Wu T. Fast surface crystallization of amorphous griseofulvin below T g. Pharm Res. 2010;27:1558\u201367. https:\/\/doi.org\/10.1007\/s11095-010-0140-8.","DOI":"10.1007\/s11095-010-0140-8."},{"key":"3041_CR68","doi-asserted-by":"publisher","unstructured":"Wang K, Sun CC. Crystal Growth of Celecoxib from Amorphous State: Polymorphism, Growth Mechanism, and Kinetics. Cryst Growth Des. 2019;19:3592\u2013600. https:\/\/doi.org\/10.1021\/acs.cgd.9b00597.","DOI":"10.1021\/acs.cgd.9b00597."},{"key":"3041_CR69","doi-asserted-by":"publisher","unstructured":"Wu T, Sun Y, Li N, De Villiers MM, Yu L. Inhibiting surface crystallization of amorphous indomethacin by nanocoating. Langmuir. 2007;23:5148\u201353. https:\/\/doi.org\/10.1021\/la070050i.","DOI":"10.1021\/la070050i."},{"key":"3041_CR70","doi-asserted-by":"publisher","unstructured":"Gui Y, Chen Y, Chen Z, Jones KJ, Yu L. Improving Stability and Dissolution of Amorphous Clofazimine by Polymer Nano-Coating. Pharm Res. 2019;36:67. https:\/\/doi.org\/10.1007\/s11095-019-2584-9.","DOI":"10.1007\/s11095-019-2584-9."},{"key":"3041_CR71","doi-asserted-by":"publisher","unstructured":"Mukesh S, Joshi P, Bansal AK, Kashyap MC, Mandal SK, Sathe V, et al. Amorphous Salts Solid Dispersions of Celecoxib: Enhanced Biopharmaceutical Performance and Physical Stability. Mol Pharm. 2021;18:2334\u201348. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00144.","DOI":"10.1021\/acs.molpharmaceut.1c00144."},{"key":"3041_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2019.110070","volume":"105","author":"RT Steipel","year":"2019","unstructured":"Steipel RT, Gallovic MD, Batty CJ, Bachelder EM, Ainslie KM. Electrospray for generation of drug delivery and vaccine particles applied in vitro and in vivo. Mater Sci Eng C. 2019;105: 110070. https:\/\/doi.org\/10.1016\/j.msec.2019.110070.","journal-title":"Mater Sci Eng C"},{"key":"3041_CR73","doi-asserted-by":"publisher","unstructured":"Correa-Soto CE, Gao Y, Indulkar AS, Zhang GGZ, Taylor LS. Role of surfactants in improving release from higher drug loading amorphous solid dispersions. Int J Pharm. 2022;625:122120.\u00a0https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122120","DOI":"10.1016\/j.ijpharm.2022.122120"},{"key":"3041_CR74","doi-asserted-by":"publisher","unstructured":"Simonelli AP, Mehta SC, Higuchi WI. Dissolution Rates of High Energy Polyvinylpyrrolidone (PVP)-Sulfathiazole Coprecipitates. J Pharm Sci. 1969;58:538\u201349.\u00a0https:\/\/doi.org\/10.1002\/jps.2600580503","DOI":"10.1002\/jps.2600580503"},{"key":"3041_CR75","doi-asserted-by":"publisher","unstructured":"Indulkar AS, Lou X, Zhang GGZ, Taylor LS. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance. Mol Pharm. 2019;16:1327\u201339. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b01261.","DOI":"10.1021\/acs.molpharmaceut.8b01261."},{"key":"3041_CR76","doi-asserted-by":"publisher","unstructured":"Saboo S, Kestur US, Flaherty DP, Taylor LS. Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition. Mol Pharm. 2020;17:1261\u201375. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b01272.","DOI":"10.1021\/acs.molpharmaceut.9b01272."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03041-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03041-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03041-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:26:59Z","timestamp":1739993219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03041-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3041"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03041-7","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}],"article-number":"47"}}